Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients.
OBJECTIVE
Erythropoietin (Epo) has neuroprotective and neurotrophic effects, and may be a novel therapeutic agent in the treatment of psychiatric disorders. We have demonstrated antidepressant-like effects of Epo on the neural and cognitive processing of facial expressions in healthy volunteers. The current study investigates the effects of Epo on the neural and cognitive response to emotional facial expressions in depressed patients.


METHODS
Nineteen acutely depressed patients were randomized to receive Epo (40,000 IU) or saline intravenously in a double-blind, parallel-group design. On day 3, we assessed neuronal responses to fearful and happy faces using functional magnetic resonance imaging and measured facial expression recognition after the scan.


RESULTS
Epo reduced neural response to fearful vs. happy faces in the amygdala and hippocampus, and to fearful faces vs. baseline in superior temporal and occipitoparietal regions 3 days after administration in acutely depressed patients. This was accompanied by a specific reduction in the recognition of fear in Epo-treated patients after the scan similar to the effects on face recognition seen with antidepressant drug treatment.


CONCLUSIONS
The present findings are similar to the effects of conventional antidepressants in acutely depressed patients and opposite to hypervigilance to negative facial expressions in depression. This highlights a potential antidepressant mechanism and warrants further investigation of Epo as a new candidate compound for treatment of depression.
Miskowiak
Kamilla W
KW
Department of Psychiatry, Copenhagen University Hospital, Hans Kirks Vej 6, DK-2200, Copenhagen, Denmark. kamilla@miskowiak.dk
Favaron
Elisa
E
Hafizi
Sepehr
S
Inkster
Becky
B
Goodwin
Guy M
GM
Cowen
Philip J
PJ
Harmer
Catherine J
CJ
D000328:Adult; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism; D003071:Cognition / Q000187:drug effects* / Q000502:physiology; D003863:Depression / Q000188:drug therapy / Q000523:psychology*; D004644:Emotions / Q000187:drug effects* / Q000502:physiology; D004921:Erythropoietin / Q000494:pharmacology / Q000627:therapeutic use*; D005149:Facial Expression; D005260:Female; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008297:Male; D010775:Photic Stimulation / Q000379:methods; D055815:Young Adult
D000928:Antidepressive Agents; D015415:Biomarkers; D004921:Erythropoietin
Am J Psychiatry. 2004 Jan;161(1):166-8
14702268
BMC Biol. 2008 Sep 09;6:37
18782446
Hum Brain Mapp. 2000 Jul;10(3):120-31
10912591
Psychopharmacology (Berl). 2009 Nov;207(1):133-42
19705104
Exp Neurol. 2009 Sep;219(1):44-52
19426730
Am J Psychiatry. 2004 Jul;161(7):1256-63
15229059
Psychiatry Res. 1992 Jun;42(3):241-51
1496056
Br J Psychiatry. 2009 Aug;195(2):102-8
19648538
Arch Gen Psychiatry. 1961 Jun;4:561-71
13688369
Biol Psychiatry. 2008 Jun 15;63(12):1155-62
18281017
Biol Psychiatry. 2002 Mar 1;51(5):370-6
11904131
Br Med J (Clin Res Ed). 1986 Feb 1;292(6516):344
3080166
Brain. 2007 Oct;130(Pt 10):2577-88
17728357
Psychiatry Res. 2003 May 30;118(2):189-96
12798984
Neuropsychopharmacology. 2003 Jan;28(1):148-52
12496951
Biol Psychiatry. 2001 Nov 1;50(9):651-8
11704071
N Engl J Med. 2008 Jan 3;358(1):55-68
18172175
Am J Psychiatry. 2007 Apr;164(4):599-607
17403973
Am J Psychiatry. 2009 Oct;166(10):1178-84
19755572
Ann N Y Acad Sci. 2003 Apr;985:389-410
12724173
J Neurosci. 1996 Jul 1;16(13):4207-21
8753882
Neuropsychopharmacology. 2008 Feb;33(3):611-8
17473836
Psychol Med. 2010 Mar;40(3):425-32
19627640
Neuroimage. 2004 Apr;21(4):1732-47
15050594
Arch Gen Psychiatry. 2004 Sep;61(9):877-89
15351766
Neuroimage. 2003 Jul;19(3):1233-9
12880848
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
14399272
Biol Psychiatry. 2006 May 1;59(9):816-20
16460693
Trends Cogn Sci. 2005 Dec;9(12):585-94
16289871
Brain Res. 2002 Oct 11;952(1):128-34
12363412
J Affect Disord. 1992 May;25(1):21-9
1624644
J Biol Chem. 2007 Aug 31;282(35):25875-83
17604282
Neuroimage. 2001 Dec;14(6):1370-86
11707093
J Neurochem. 2005 Apr;93(2):412-21
15816864
Psychol Med. 1998 Sep;28(5):1027-38
9794010
J Affect Disord. 1994 Oct;32(2):133-7
7829765
Mol Psychiatry. 2007 Feb;12(2):206-20
17033631
J Drug Target. 2010 Apr;18(3):179-90
19807216
Biol Psychiatry. 2004 Mar 15;55(6):578-87
15013826
J Nerv Ment Dis. 1999 Oct;187(10):595-602
10535652
Nat Rev Neurosci. 2005 Jun;6(6):484-94
15928718
J Neurosci Methods. 2002 Aug 30;118(2):115-28
12204303
Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31
10984541
Cancer Treat Rev. 2004 Oct;30(6):563-75
15325036
Mol Psychiatry. 2000 Nov;5(6):578-93
11126389
Neuropsychologia. 2007 Jan 7;45(1):174-94
16854439
Nat Rev Neurosci. 2006 Feb;7(2):137-51
16429123
Nat Rev Neurosci. 2008 Oct;9(10):788-96
18784657
Biol Psychiatry. 2007 Dec 1;62(11):1244-50
17553466
Behav Res Ther. 1995 Sep;33(7):755-70
7677713
Br J Psychiatry. 1982 Nov;141:518-23
7150890